Industry

MINNEAPOLIS–(BUSINESS WIRE)–Provation, a leading provider of clinical productivity software, announces the launch of Provation® Mira Documentation Assist, a voice-driven documentation capability within its cloud-based GI procedure platform, Provation® Apex, enabling real-time structured documentation during procedures. This hands-free technology allows clinicians to document in real-time by simply speaking, reducing the need for manual data entry and … [Read more…]

New collection closes the gap between leadership development and well-being support as organizations seek to strengthen leaders and consolidate fragmented point solutions SAN FRANCISCO–(BUSINESS WIRE)–As rising healthcare costs, workforce stress, and constant organizational change place increasing pressure on managers and leaders, employers are rethinking how they develop talent. Today, Modern Health, a leading global workplace … [Read more…]

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company’s STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, … [Read more…]

FRANKFURT, Germany–(BUSINESS WIRE)–Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, is pleased to announce that BELOTERO® Balance has received EU approval for two additional indications: the treatment of infraorbital hollow (including the tear trough) and horizontal forehead lines1*. “With these new approvals, BELOTERO® Balance further strengthens its position as a versatile hyaluronic acid dermal … [Read more…]

Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 Results demonstrate the potential for Camzyos to be the first targeted pharmacological therapy for the treatment of oHCM in adolescents Safety profile of Camzyos in adolescents was similar to established profile in … [Read more…]

Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure Results support initiation of Phase 2b clinical trial of tonlamarsen in patients with acute severe hypertension SOUTH SAN FRANCISCO, Calif., & PRINCETON, N.J.–(BUSINESS WIRE)–#ACC26—Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root … [Read more…]

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device (SaMD) that detects early signs of PH, a serious and progressive condition affecting the lungs and right side of the heart. The algorithm, which previously received FDA Breakthrough … [Read more…]

High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Cobenfy—Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when switching adult outpatients with schizophrenia from … [Read more…]

DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website. The third‑party article incorrectly claimed that Panna … [Read more…]